Cargando…

Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 gag

Detalles Bibliográficos
Autores principales:	Qiu, Jian-Tai, Chang, Ting-Chang, Lin, Cheng-Tao, Chen, Yi-Ming, Li, Fran Q, Soong, Yung-Kuei, Lai, Chyong-Huey
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716872/ http://dx.doi.org/10.1186/1742-4690-3-S1-P50

Ejemplares similares

Effect of AcHERV-GmCSF as an Influenza Virus Vaccine Adjuvant
por: Choi, Hyo Jung, et al.
Publicado: (2015)

Functional characterization of GM-CSF induced monocyte subsets
por: Däbritz, J, et al.
Publicado: (2008)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

Effect of Multiple Vaccinations with Tumor Cell-Based Vaccine with Codon-Modified GM-CSF on Tumor Growth in a Mouse Model
por: Qiu, Jiantai Timothy, et al.
Publicado: (2019)

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
por: Greene, Julia, et al.
Publicado: (2014)

Innate and adaptive immunity contribute to the anti-tumor mechanisms of action of OncoVEX(mGM-CSF)
por: Cooke, Keegan, et al.
Publicado: (2015)

GM-CSF-Dependent Inflammatory Pathways
por: Hamilton, John A.
Publicado: (2019)

Development of Dendritic Cells from GM-CSF(-/-) Mice in vitro : GM-CSF Enhances Production and Survival of Cells
por: Ni, Keping, et al.
Publicado: (2001)

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes
por: Bystrom, Jonas, et al.
Publicado: (2017)

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity
por: Pykhtina, Mariya, et al.
Publicado: (2021)

Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2
por: Wu, Hsien-Ming, et al.
Publicado: (2013)

Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
por: Shiomi, Aoi, et al.
Publicado: (2015)

A Review of GM-CSF Therapy in Sepsis
por: Mathias, Brittany, et al.
Publicado: (2015)

The efficacy and safety of targeting GM-CSF in arthritis
por: Bykerk, Vivian P
Publicado: (2020)

GM-CSF: Orchestrating the Pulmonary Response to Infection
por: McCormick, Thomas S., et al.
Publicado: (2022)

Role of GM-CSF in lung balance and disease
por: Chen, Yingzi, et al.
Publicado: (2023)

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC
por: Hilton, Traci, et al.
Publicado: (2014)

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC
por: Sanborn, Rachel, et al.
Publicado: (2015)

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
por: Bosteels, Cedric, et al.
Publicado: (2022)

Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSF
por: Zhang, Song-Nan, et al.
Publicado: (2011)

GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges
por: Robinson, H, et al.
Publicado: (2012)

GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease
por: Zhang, Can, et al.
Publicado: (2011)

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
por: He, Kai, et al.
Publicado: (2022)

Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
por: Jackson, Doreen, et al.
Publicado: (2015)

Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials
por: de Gruijl, Tanja D, et al.
Publicado: (2015)

Characterisation of a spumavirus Gag protein
por: Goldstone, David C, et al.
Publicado: (2013)

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
por: Perales, Miguel-Angel, et al.
Publicado: (2008)

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases
por: Chen, Tempe K, et al.
Publicado: (2022)

G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis
por: Castellani, Stefano, et al.
Publicado: (2019)

Delivery of GM-CSF to Protect against Influenza Pneumonia
por: Subramaniam, Renuka, et al.
Publicado: (2015)

GM-CSF as a therapeutic target in autoimmune diseases
por: Shiomi, Aoi, et al.
Publicado: (2016)

Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update
por: Lotfi, Noushin, et al.
Publicado: (2019)

GM-CSF: A Promising Target in Inflammation and Autoimmunity
por: Lee, Kevin M C, et al.
Publicado: (2020)

GM-CSF Dependent Differential Control of Mycobacterium tuberculosis Infection in Human and Mouse Macrophages: Is Macrophage Source of GM-CSF Critical to Tuberculosis Immunity?
por: Mishra, Abhishek, et al.
Publicado: (2020)

The addition of granulocyte macrophage colony stimulating factor (GM-CSF) to juvenile systemic lupus erythematosus serum can reduce abnormal neutrophil apoptosis
por: Midgley, AJ, et al.
Publicado: (2008)

Induction of HIV-specific T-cell responses by gag
por: Van Gulck, Ellen, et al.
Publicado: (2006)

P09-18. Cw*0303/0304 HIV specific CTL response toward GagYL9 select for HIV escape variants with low fitness that is compensated by intra-codon variation
por: Honeyborne, I, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_uef67vt1d7eqegg4quu1qjq22j